Aurora Cannabis (NYSE:ACB) Pops On Outlook, Falls On Results

→ Putin and other countries have a plan (From Whats On Finance) (Ad)
Aurora Cannabis (NYSE:ACB) Pops On Outlook, Falls On ResultsAurora Cannabis Transformation Is Nearly Complete

Aurora Cannabis (NYSE:ACB) was one of the first Canadian cannabis companies to accept the truth. The Canadian cannabis market is not nearly as large as the early data suggested. It’s still quite large but at today’s valuation only half of what it should be. And that led the company to make some hard decisions. Decisions that are still impacting the company today and have it set up for profits next quarter. Yes, that’s right, we have a Canadian Cannabis on the verge of profitability.

Aurora Cannabis Beats The Consensus, Loss Grows

Aurora Cannabis beat the consensus for revenue by 670 basis points to deliver a slight improvement on a QoQ basis. The $67.81 million (Canadian) beat the consensus by $4.22 million on mixed results in the underlying businesses. The Canadian Consumer segment saw its revenue fall -3.0% while the more lucrative Medical segment grew 4% on strength in International markets. The International Medical segment grew 41% from the prior quarter on strength in Europe and U.S. CBD.

Moving down, adjusted gross margins came in strong at 48% but are down 2.0% on a YOY basis. When excluding costs related to the ramp of production at the Aurora Nordic 1 facility margins come in at a much better 52.%. SG&A expense fell 19.6% due to restructuring efforts that termination costs and the closing of Canadian production facilities. On the bottom line, the adjusted loss came in at $57.9 million or up on a QoQ basis but there is a mitigating factor. Excluding the restructuring costs and fees (one time items) the company’s loss shrank to a mere $10.5 million.

In terms of guidance, the company says it will continue to cut costs. As of now, there are plans to shut down another two production facilities to bring the companies operations more in-line with the market. As for profitability, the company says it is on track for profitability in the fiscal 2nd quarter of 2021 or the current quarter on a calendar basis. That’s big news. Until then, investors can rest assured the company’s $250 million cash-balance is enough to sustain operations.

"We continue to take the necessary steps to execute our plan and transform our business to achieve sustainable profitability, and ultimately positive cash flow," stated Miguel Martin, Chief Executive Officer of Aurora Cannabis. "While we are not satisfied with our past performance in the growing Canadian consumer business, we have a sense of urgency in the execution of our tactical plan to grow profitable market share. Our efforts are directed at delivering the highest quality products, refocusing on our leading premium and ultra-premium brands, better allocating our sales and marketing spend, and executing key account partnerships at both the province and retail levels."

The Technical Outlook: Aurora Isn’t A Buy Yet

Shares of Aurora began moving higher days before the earnings release on the hopes of U.S. legalization. The U.S. market is an instant win for Cannabis and the Joe Biden victory is a step in the right direction. What investors need to be cautious of in this regard is the Senate. The Senate is likely to block any major cannabis legislation for the next two years. Until then we have Aurora’s prospects of profitability to drive share prices and that is still questionable.

Regarding the charts, Aurora popped after the earnings release but is giving up all the gains in the post-market action. The stock looks like it is confirming the overall downtrend and will likely remain at these low levels for the foreseeable future. In the meantime, watch for confirmation of support in the $4 to $10 region and use them as entry points to start loading up on this stock.

Aurora Cannabis (NYSE:ACB) Pops On Outlook, Falls On Results

Should you invest $1,000 in Aurora Cannabis right now?

Before you consider Aurora Cannabis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurora Cannabis wasn't on the list.

While Aurora Cannabis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report
Thomas Hughes

About Thomas Hughes


Contributing Author

Technical and Fundamental Analysis


Thomas Hughes has been a contributing writer for MarketBeat since 2019.

Areas of Expertise

Technical analysis, the S&P 500; retail, consumer, consumer staples, dividends, high-yield, small caps, technology, economic data, oil, cryptocurrencies


Associate of Arts in Culinary Technology

Past Experience

Market watcher, trader and investor for numerous websites. Founded Passive Market Intelligence LLC to provide market research insights. 

Featured Articles and Offers

Search Headlines: